Therapeutic Drug Monitoring (TDM) Market: Global Market Size, Dynamics, Regional Share, Trends, Competitor Analysis 2017 to 2021 and Forecast 2022 to 2028

$ PRICE - $ 2,000.00$ 6,900.00

Therapeutic Drug Monitoring (TDM) Market: By Drug Type (Antibiotics, Addiction Therapeutics, Alzheimer Disease, Analeptics, Analgesics, Antiarrhythmic, Anticancer, Anticoagulants, Antidepressants, Antiepileptics, Anti-HIV, Antihypertensive, Antipsychotics, Hormones, Immuno-Suppressants, Antifungals), By Technology (Immuno- Assay, Mass Spectrometry, GC-MS/MS, Others), By End User (Hospital Laboratories, Private Laboratories) and Geography

 

$ PRICE - $ 2,000.00$ 6,900.00
Clear selection
Clear
$ PRICE - $ 2,000.00$ 6,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Categories: ,

Report

Description

Therapeutic Drug Monitoring Market size was valued at USD 2.2 billion in 2021. It is expected to reach a value of USD 3.5 billion by 2028, witnessing at a CAGR rate of 4.9% from 2022-2028. Therapeutic Drug Monitoring is a measurement of drug concentrations or drug metabolites in plasma. It is usually carried out for narrow therapeutic index drugs. Therapeutic drug monitoring is the clinical assessment of drug’s pharmacokinetic properties. TDM helps in reduce drug toxicity, enhance drug efficacy and diagnostic purpose. Various drug molecules usually monitored at clinical practice. For example: drugs like digoxin, cyclosporin, phenytoin, carbamazepine and valproic acid, among others. Tricyclic antidepressants (TCAs) such as Amitriptyline, Nortriptyline, Imipramine, and Clomipramine are frequently preferred for TDM due to their slow onset of action the difficulty of assessing dose-effect, and the marked interindividual variability of steady-state plasma concentration. In general, LC-MS/MS is highly preferred for TDM of tricyclic antidepressants due to structural similarity of the drugs. Immunosuppressant drugs are mostly used in organ transplantation cases. Patients using ISD’s commonly undergo TDM owing to their narrow therapeutic index, variability in blood concentrations between individuals and severe adverse effects. In terms of technology, LC-MS/MS accounts for more than USD 730 Million in 2018 followed by immunoassay, Others and GC/GC-MS. In terms of value, LC-MS/MS dominate the global TDM market followed by the immunoassays segment owing to its sensitivity, specificity towards the identification analytes and simultaneous analysis of the multiple drugs and analytes in the blood. However, in terms of volume Immunoassays dominate the market and they are cost effective when compared with other reagents. The report gives historical, current, and future market sizes (US$ Bn) based on Technology, Drug class, and Geography. This report studies market dynamics elaborately to identify the current trends & drivers, future opportunities, and possible challenges to the key stakeholders operating in the market. In addition, the report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition.

Key Development:

In March 2022, Beckman Coulter, a global clinical diagnostics leader, announced that the company will introduce new antipsychotic drug tests to laboratories and clinicians to address an unmet clinical need for 69 million people with serious mental conditions worldwide. In a new agreement with Saladax Biomedical, Inc., Beckman Coulter will distribute the tests designed to measure blood levels of antipsychotic drugs prescribed to treat patients with serious mental illness (SMI), such as Schizophrenia and Bipolar Disorder. These new assays are developed using an innovative nanoparticle technology and empower health care professionals with data to monitor psychiatric drugs prescribed in treatment of psychosis: Clozapine, Risperidone/Paliperidone, Olanzapine, Quetiapine, Aripiprazole.

In August 2019, Ortho Clinical Diagnostics, a global leader in in-vitro diagnostics, in collaboration with Thermo Fisher Scientific, has expanded Drugs of Abuse and Therapeutic Drug Assay menus on MicroTip-capable VITROS® Systems to enable testing for fentanyl, a commonly abused opioid, and tricyclic antidepressant (TCA), which has a narrow safe therapeutic range.

Therapeutic Drug Monitoring (TDM) Market

MARKET SUMMARY
-
4.9% CAGR
  • Study Period– 2022 – 2028
  • Base Year– 2021
  • CAGR– 4.9%
  • Largest Market– North America
  • Fastest Growing Market– Asia Pacific

Therapeutic Drug Monitoring (TDM) Market

  • In 2018, more than 400 Million TDM tests were conducted around the globe and projected to reach more than 600 Million TDM tests by 2028. Immunoassay and LC-MS/MS are the top technology platforms for analyzing the TDM samples and they both analyzed more than 250 Million TDM samples in 2018.
  • North America TDM market has a market share of 56% in 2018 followed by EMEA with 31.2%. USA dominates the therapeutic drug monitoring market in North America and global level.
  • The top four drug classes: Antidepressants, Immunosuppressants, Hormones, and Analgesics accounts to have 55.7% market share in the global therapeutic drug monitoring market.
  • Among the antidepressants, Citalopram is highly preferred for TDM due to the racemic mixture of the compound. Moreover, the elimination half-life for the drug is approximately 33 hours
Market Leaders
  • ARK Diagnostics, Inc.
  • Beckman Coulter
  • Ortho Clinical Diagnostics
  • Sekisui Diagnostics
  • SJK Global, LLC
  • Chromsystems
  • Meridian Healthcare S.R.L.
  • Randox Laboratories Ltd
  • Sekisui Medical Co. Ltd.
  • Thermo Fisher Scientific
Drivers and Restrains

Global Therapeutic Drug Monitoring (TDM) Market

Increase in the number of organ transplantation cases around the globe expected to fuel the therapeutic drug monitoring over the forecast period. As per the World Health Organization (WHO), in November 2016, approximately 100,791 people await kidney transplants and Over 3,000 new patients are added to the kidney waiting list each month. Moreover, adverse effects associated with the drugs, and development of technologically advanced instruments are enables the growth of therapeutic drug monitoring market over the forecast years. Moreover, rise in R&D activities for the development of test kits, rise in adoption of therapeutic drug monitoring in emerging countries, and development in healthcare infrastructure are anticipated to propel the global therapeutic drug monitoring market over the forecast years.


North America accounted for larger revenue share

Global Therapeutic Drug Monitoring (TDM) Market

North America accounted for larger revenue share in global therapeutic drug monitoring market with moderate CAGR. Increase in the adoption of therapeutic drug assays by the healthcare professionals, innovation of advanced test kits by the market players, and surge in prevalence of chronic diseases are boost the market in the region. Asia Pacific market projected to grow at significant rate owing to increase in number of patients with chronic diseases in India, China, and japan, development in healthcare infrastructure, and launch of newer test kits into market are expected to enhance the market over the forecast timeframe.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Key Features of the Report

  • The report provides granular level information about the market size, regional market share, historic market (2017-2021) and forecast (2022-2028)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Global Therapeutic Drug Monitoring (TDM) Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

The global therapeutic drug monitoring market is valued at USD 2.2 Billion in 2021 and projected to reach 3.5 Billion by 2028

The top TDM drug classes are Antidepressants (17.9%), Immunosuppressants (14.3%), Hormones (13.2%), Analgesics (10.4%), and Antiepileptics (9%)

LC-MS/MS segment dominates the therapeutic drug monitoring market in terms of both value and volume.

North America (USA) and Europe (Germany and UK) are the potential markets in the therapeutic drug monitoring market.


Report

Table Of Content

1. Executive summary
2. Global Therapeutic Drug Monitoring (TDM) Market Introduction
2.1. Global Therapeutic Drug Monitoring (TDM) Market – Taxonomy
2.2. Global Therapeutic Drug Monitoring (TDM) Market –Definitions
2.2.1. By Drug Type
2.2.2. By Technology
2.2.3. By End User
2.2.4. By Region
3. Global Therapeutic Drug Monitoring (TDM) Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Reimbursement Scenario for Top 5 Countries
3.6. Global Therapeutic Drug Monitoring (TDM) Market Dynamics – Factors Impact Analysis
4. Global Therapeutic Drug Monitoring (TDM) Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028
4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Millions and Volume in Millions)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Therapeutic Drug Monitoring (TDM) Market, By Drug Type, 2017 – 2021 and Forecast, 2018 – 2028
5.1. Antibiotics
5.1.1. Antibiotics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.1.3.1. Chloramphenicol
5.1.3.2. Linezolid
5.1.3.3. Piperacillin
5.1.3.4. Rifampicin
5.1.3.5. Tazobactam
5.1.3.6. Vancomycin
5.1.3.7. Gentamicin
5.1.3.8. Amikacin
5.1.3.9. Tobramycin
5.1.3.10. Teicoplanin
5.1.3.11. Ceftazidime
5.1.3.12. Meropenem
5.1.3.13. Nafcillin
5.1.3.14. Ticarcillin
5.2. Addiction Therapeutics
5.2.1. Addiction Therapeutics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.2.3.1. Buprenorphine
5.2.3.2. Methadone
5.2.3.3. Naltrexone
5.2.3.4. Propoxyphene
5.2.3.5. Tapentadol
5.3. Alzheimer Disease
5.3.1. Alzheimer Disease Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.3.3.1. Donezepil
5.3.3.2. Galantamine
5.3.3.3. Memantine
5.4. Analeptics
5.4.1. Analeptics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.4.3.1. Caffeine
5.4.3.2. Theophylline
5.5. Analgesics
5.5.1. Analgesics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
5.5.3.1. Acetaminophen
5.5.3.2. Ibuprofen
5.5.3.3. Naproxen
5.5.3.4. Salicylate
5.5.3.5. Tramadol
5.6. Antiarrhythmic
5.6.1. Antiarrythmic Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.6.3. Market Opportunity Analysis
5.6.3.1. Amiodarone
5.6.3.2. Digoxin
5.6.3.3. Flecainide
5.6.3.4. Mexiletine
5.6.3.5. Verapamil
5.6.3.6. N-acetylprocainamide, NAPA
5.6.3.7. Digitoxin
5.6.3.8. Lidocaine
5.6.3.9. Procainimide
5.6.3.10. Quinidine
5.7. Anticancer
5.7.1. Anticancer Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
5.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.7.3. Market Opportunity Analysis
5.7.3.1. 5-Fluorouracil
5.7.3.2. Docetaxel
5.7.3.3. Methotrexate
5.7.3.4. Mylmatinib
5.7.3.5. Paclitaxel
5.7.3.6. Imatinib
5.7.3.7. Busulfan
5.8. Anticoagulants
5.8.1. Anticoagulants Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
5.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.8.3. Market Opportunity Analysis
5.8.3.1. Dabigatran
5.8.3.2. Warfarin
5.9. Antidepressants
5.9.1. Antidepressants Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
5.9.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.9.3. Market Opportunity Analysis
5.9.3.1. Citalopram
5.9.3.2. Fluoxetine
5.9.3.3. Fluvoxamine
5.9.3.4. Sertraline
5.9.3.5. Venlafaxine
5.9.3.6. Desmethylfluoxetine
5.9.3.7. Trazodone
5.9.3.8. Protriptyline
5.9.3.9. Nortriptyline
5.9.3.10. Imipramine
5.9.3.11. Desipramine
5.9.3.12. Doxepin
5.9.3.13. Clomipramine
5.9.3.14. Bupropion
5.9.3.15. Amitriptyline
5.9.3.16. Nortriptyline
5.10. Antiepileptics
5.10.1. Antiepileptics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
5.10.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.10.3. Market Opportunity Analysis
5.10.3.1. Ethosuximide
5.10.3.2. Felbamate
5.10.3.3. Gabapentin
5.10.3.4. Lamotrigine
5.10.3.5. Pregabaline
5.10.3.6. Topiramate
5.10.3.7. Zonisamide
5.10.3.8. Carbamazepine
5.10.3.9. Valproic Acid
5.10.3.10. Lacosamide
5.10.3.11. Levetiracetam
5.10.3.12. Phenobarbital
5.10.3.13. Phenytoin
5.10.3.14. Rufinamide
5.10.3.15. Tiagabine
5.10.3.16. Vigabatrin
5.10.3.17. Primidone
5.11. Anti-HIV
5.11.1. Anti-HIV Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
5.11.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.11.3. Market Opportunity Analysis
5.11.3.1. Atazanavir
5.11.3.2. Indinavir
5.11.3.3. Lopinavir
5.11.3.4. Nelfinavir
5.11.3.5. Ritonavir
5.11.3.6. Saquinavir
5.11.3.7. Darunavir
5.11.3.8. Fosamprenavir
5.11.3.9. Tipranavir
5.11.3.10. Efavirenz
5.11.3.11. Etravirine
5.11.3.12. Nevirapine
5.11.3.13. Rilpivirine
5.12. Antihypertensive
5.12.1. Antihypertensive Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
5.12.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.12.3. Market Opportunity Analysis
5.12.3.1. Propronolol
5.13. Antipsychotics
5.13.1. Antipsychotics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
5.13.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.13.3. Market Opportunity Analysis
5.13.3.1. Aripiprazole
5.13.3.2. Clozapine
5.13.3.3. Haloperidol
5.13.3.4. Olanzapine
5.13.3.5. Ziprasidone
5.13.3.6. Chlorpromazine
5.13.3.7. Lithium
5.13.3.8. Lurasidone
5.13.3.9. Paliperidone
5.13.3.10. Perphenazine
5.13.3.11. Quetiapine
5.13.3.12. Risperidone
5.13.3.13. Thiothixene
5.14. Hormones
5.14.1. Hormones Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
5.14.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.14.3. Market Opportunity Analysis
5.14.3.1. T3
5.14.3.2. T4
5.14.3.3. Corticosteroids
5.14.3.4. TSH
5.15. Immuno-Suppressants
5.15.1. Immuno-Suppressants Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
5.15.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.15.3. Market Opportunity Analysis
5.15.3.1. Cyclosporin A
5.15.3.2. Everolimus
5.15.3.3. Mycophenolic acid
5.15.3.4. Sirolimus
5.15.3.5. Tacrolimus
5.16. Antifungals
5.16.1. Antifungals Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
5.16.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.16.3. Market Opportunity Analysis
5.16.3.1. Fluconazole
5.16.3.2. Itraconazole
5.16.3.3. Voriconazole
5.16.3.4. Posoconazole
6. Global Therapeutic Drug Monitoring (TDM) Market Forecast, By Technology Type, 2017 – 2021 and Forecast, 2022 – 2028
6.1. Immuno- Assay
6.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume, Millions))
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Mass Spectrometry
6.2.1. LC-MS/MS
6.2.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume, Millions))
6.2.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.1.3. Market Opportunity Analysis
6.3. GC-MS/MS
6.3.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume, Millions))
6.3.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.1.3. Market Opportunity Analysis
6.4. Others (Electrophoresis, Proteomics, etc.)
6.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume, Millions))
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
7. Global Therapeutic Drug Monitoring (TDM) Market Forecast, By End-User Type, 2017 – 2021 and Forecast, 2022 – 2028
7.1. Hospital Laboratories
7.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions))
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Private Laboratories
7.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions))
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
8. Global Therapeutic Drug Monitoring (TDM) Market Analysis, By Region, 2017 – 2021 and Forecast, 2018 – 2024 ((Revenue, USD Millions) (Volume Millions))
8.1. North America
8.1.1. Market Analysis, 2017 – 2021 and Forecast, 2018 – 2024 ((Revenue, USD Millions) (Volume, Millions))
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Europe, Middle East & Africa
8.2.1. Market Analysis, 2017 – 2021 and Forecast, 2018 – 2024 ((Revenue, USD Millions) (Volume, Millions))
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Latin America
8.3.1. Market Analysis, 2017 – 2021 and Forecast, 2018 – 2024 ((Revenue, USD Millions) (Volume, Millions))
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Asia Pacific
8.4.1. Market Analysis, 2017 – 2021 and Forecast, 2018 – 2024 ((Revenue, USD Millions) (Volume, Millions))
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Global Therapeutic Drug Monitoring (TDM) Market – Opportunity Analysis Index, By Drug Type, By Technology, and Region, 2018 – 2024
9. North America Therapeutic Drug Monitoring (TDM) Market Analysis, 2017 – 2021 and Forecast, 2018 – 2028
9.1. Antibiotics
9.1.1. Antibiotics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.1.3. Market Opportunity Analysis
9.1.3.1. Chloramphenicol
9.1.3.2. Linezolid
9.1.3.3. Piperacillin
9.1.3.4. Rifampicin
9.1.3.5. Tazobactam
9.1.3.6. Vancomycin
9.1.3.7. Gentamicin
9.1.3.8. Amikacin
9.1.3.9. Tobramycin
9.1.3.10. Teicoplanin
9.1.3.11. Ceftazidime
9.1.3.12. Meropenem
9.1.3.13. Nafcillin
9.1.3.14. Ticarcillin
9.2. Addiction Therapeutics
9.2.1. Addiction Therapeutics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.2.3. Market Opportunity Analysis
9.2.3.1. Buprenorphine
9.2.3.2. Methadone
9.2.3.3. Naltrexone
9.2.3.4. Propoxyphene
9.2.3.5. Tapentadol
9.3. Alzheimer Disease
9.3.1. Alzheimer Disease Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.3.3. Market Opportunity Analysis
9.3.3.1. Donezepil
9.3.3.2. Galantamine
9.3.3.3. Memantine
9.4. Analeptics
9.4.1. Analeptics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.4.3. Market Opportunity Analysis
9.4.3.1. Caffeine
9.4.3.2. Theophylline
9.5. Analgesics
9.5.1. Analgesics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.5.3. Market Opportunity Analysis
9.5.3.1. Acetaminophen
9.5.3.2. Ibuprofen
9.5.3.3. Naproxen
9.5.3.4. Salicylate
9.5.3.5. Tramadol
9.6. Antiarrhythmic
9.6.1. Antiarrythmic Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
9.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.6.3. Market Opportunity Analysis
9.6.3.1. Amiodarone
9.6.3.2. Digoxin
9.6.3.3. Flecainide
9.6.3.4. Mexiletine
9.6.3.5. Verapamil
9.6.3.6. N-acetylprocainamide, NAPA
9.6.3.7. Digitoxin
9.6.3.8. Lidocaine
9.6.3.9. Procainimide
9.6.3.10. Quinidine
9.7. Anticancer
9.7.1. Anticancer Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
9.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.7.3. Market Opportunity Analysis
9.7.3.1. 5-Fluorouracil
9.7.3.2. Docetaxel
9.7.3.3. Methotrexate
9.7.3.4. Mylmatinib
9.7.3.5. Paclitaxel
9.7.3.6. Imatinib
9.7.3.7. Busulfan
9.8. Anticoagulants
9.8.1. Anticoagulants Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
9.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.8.3. Market Opportunity Analysis
9.8.3.1. Dabigatran
9.8.3.2. Warfarin
9.9. Antidepressants
9.9.1. Antidepressants Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
9.9.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.9.3. Market Opportunity Analysis
9.9.3.1. Citalopram
9.9.3.2. Fluoxetine
9.9.3.3. Fluvoxamine
9.9.3.4. Sertraline
9.9.3.5. Venlafaxine
9.9.3.6. Desmethylfluoxetine
9.9.3.7. Trazodone
9.9.3.8. Protriptyline
9.9.3.9. Nortriptyline
9.9.3.10. Imipramine
9.9.3.11. Desipramine
9.9.3.12. Doxepin
9.9.3.13. Clomipramine
9.9.3.14. Bupropion
9.9.3.15. Amitriptyline
9.9.3.16. Nortriptyline
9.10. Antiepileptics
9.10.1. Antiepileptics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
9.10.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.10.3. Market Opportunity Analysis
9.10.3.1. Ethosuximide
9.10.3.2. Felbamate
9.10.3.3. Gabapentin
9.10.3.4. Lamotrigine
9.10.3.5. Pregabaline
9.10.3.6. Topiramate
9.10.3.7. Zonisamide
9.10.3.8. Carbamazepine
9.10.3.9. Valproic Acid
9.10.3.10. Lacosamide
9.10.3.11. Levetiracetam
9.10.3.12. Phenobarbital
9.10.3.13. Phenytoin
9.10.3.14. Rufinamide
9.10.3.15. Tiagabine
9.10.3.16. Vigabatrin
9.10.3.17. Primidone
9.11. Anti-HIV
9.11.1. Anti-HIV Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
9.11.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.11.3. Market Opportunity Analysis
9.11.3.1. Atazanavir
9.11.3.2. Indinavir
9.11.3.3. Lopinavir
9.11.3.4. Nelfinavir
9.11.3.5. Ritonavir
9.11.3.6. Saquinavir
9.11.3.7. Darunavir
9.11.3.8. Fosamprenavir
9.11.3.9. Tipranavir
9.11.3.10. Efavirenz
9.11.3.11. Etravirine
9.11.3.12. Nevirapine
9.11.3.13. Rilpivirine
9.12. Antihypertensive
9.12.1. Antihypertensive Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
9.12.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.12.3. Market Opportunity Analysis
9.12.3.1. Propronolol
9.13. Antipsychotics
9.13.1. Antipsychotics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
9.13.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.13.3. Market Opportunity Analysis
9.13.3.1. Aripiprazole
9.13.3.2. Clozapine
9.13.3.3. Haloperidol
9.13.3.4. Olanzapine
9.13.3.5. Ziprasidone
9.13.3.6. Chlorpromazine
9.13.3.7. Lithium
9.13.3.8. Lurasidone
9.13.3.9. Paliperidone
9.13.3.10. Perphenazine
9.13.3.11. Quetiapine
9.13.3.12. Risperidone
9.13.3.13. Thiothixene
9.14. Hormones
9.14.1. Hormones Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
9.14.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.14.3. Market Opportunity Analysis
9.14.3.1. T3
9.14.3.2. T4
9.14.3.3. Corticosteroids
9.14.3.4. TSH
9.15. Immuno-Suppressants
9.15.1. Immuno-Suppressants Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
9.15.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.15.3. Market Opportunity Analysis
9.15.3.1. Cyclosporin A
9.15.3.2. Everolimus
9.15.3.3. Mycophenolic acid
9.15.3.4. Sirolimus
9.15.3.5. Tacrolimus
9.16. Antifungals
9.16.1. Antifungals Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
9.16.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.16.3. Market Opportunity Analysis
9.16.3.1. Fluconazole
9.16.3.2. Itraconazole
9.16.3.3. Voriconazole
9.16.3.4. Posoconazole
9.17. Immuno- Assay
9.17.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions))
9.17.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.17.3. Market Opportunity Analysis
9.18. Mass Spectrometry
9.18.1. LC-MS/MS
9.18.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions))
9.18.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.18.1.3. Market Opportunity Analysis
9.18.2. GC-MS/MS
9.18.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions))
9.18.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.18.2.3. Market Opportunity Analysis
9.19. Others (Electrophoresis, Proteomics, etc.)
9.19.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions))
9.19.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.19.3. Market Opportunity Analysis
9.20. North America Therapeutic Drug Monitoring (TDM) Market By End User
9.20.1. Hospital Laboratories
9.20.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions))
9.20.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.20.1.3. Market Opportunity Analysis
9.20.2. Private Laboratories
9.20.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions))
9.20.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.20.2.3. Market Opportunity Analysis
9.21. North America Therapeutic Drug Monitoring (TDM) Market By Country
9.21.1. United States
9.21.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions))
9.21.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.21.1.3. Market Opportunity Analysis
9.21.2. Canada
9.21.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions))
9.21.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.21.2.3. Market Opportunity Analysis
9.22. North America Therapeutic Drug Monitoring (TDM) Market Dynamics – Trends
10. Europe, Middle East & Africa Therapeutic Drug Monitoring (TDM) Market Analysis, 2017 – 2021 and Forecast, 2018 – 2028
10.1. Antibiotics
10.1.1. Antibiotics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
10.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
10.1.3. Market Opportunity Analysis
10.1.3.1. Chloramphenicol
10.1.3.2. Linezolid
10.1.3.3. Piperacillin
10.1.3.4. Rifampicin
10.1.3.5. Tazobactam
10.1.3.6. Vancomycin
10.1.3.7. Gentamicin
10.1.3.8. Amikacin
10.1.3.9. Tobramycin
10.1.3.10. Teicoplanin
10.1.3.11. Ceftazidime
10.1.3.12. Meropenem
10.1.3.13. Nafcillin
10.1.3.14. Ticarcillin
10.2. Addiction Therapeutics
10.2.1. Addiction Therapeutics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
10.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
10.2.3. Market Opportunity Analysis
10.2.3.1. Buprenorphine
10.2.3.2. Methadone
10.2.3.3. Naltrexone
10.2.3.4. Propoxyphene
10.2.3.5. Tapentadol
10.3. Alzheimer Disease
10.3.1. Alzheimer Disease Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
10.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
10.3.3. Market Opportunity Analysis
10.3.3.1. Donezepil
10.3.3.2. Galantamine
10.3.3.3. Memantine
10.4. Analeptics
10.4.1. Analeptics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
10.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
10.4.3. Market Opportunity Analysis
10.4.3.1. Caffeine
10.4.3.2. Theophylline
10.5. Analgesics
10.5.1. Analgesics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
10.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
10.5.3. Market Opportunity Analysis
10.5.3.1. Acetaminophen
10.5.3.2. Ibuprofen
10.5.3.3. Naproxen
10.5.3.4. Salicylate
10.5.3.5. Tramadol
10.6. Antiarrhythmic
10.6.1. Antiarrythmic Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
10.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
10.6.3. Market Opportunity Analysis
10.6.3.1. Amiodarone
10.6.3.2. Digoxin
10.6.3.3. Flecainide
10.6.3.4. Mexiletine
10.6.3.5. Verapamil
10.6.3.6. N-acetylprocainamide, NAPA
10.6.3.7. Digitoxin
10.6.3.8. Lidocaine
10.6.3.9. Procainimide
10.6.3.10. Quinidine
10.7. Anticancer
10.7.1. Anticancer Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
10.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
10.7.3. Market Opportunity Analysis
10.7.3.1. 5-Fluorouracil
10.7.3.2. Docetaxel
10.7.3.3. Methotrexate
10.7.3.4. Mylmatinib
10.7.3.5. Paclitaxel
10.7.3.6. Imatinib
10.7.3.7. Busulfan
10.8. Anticoagulants
10.8.1. Anticoagulants Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
10.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
10.8.3. Market Opportunity Analysis
10.8.3.1. Dabigatran
10.8.3.2. Warfarin
10.9. Antidepressants
10.9.1. Antidepressants Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
10.9.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
10.9.3. Market Opportunity Analysis
10.9.3.1. Citalopram
10.9.3.2. Fluoxetine
10.9.3.3. Fluvoxamine
10.9.3.4. Sertraline
10.9.3.5. Venlafaxine
10.9.3.6. Desmethylfluoxetine
10.9.3.7. Trazodone
10.9.3.8. Protriptyline
10.9.3.9. Nortriptyline
10.9.3.10. Imipramine
10.9.3.11. Desipramine
10.9.3.12. Doxepin
10.9.3.13. Clomipramine
10.9.3.14. Bupropion
10.9.3.15. Amitriptyline
10.9.3.16. Nortriptyline
10.10. Antiepileptics
10.10.1. Antiepileptics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
10.10.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
10.10.3. Market Opportunity Analysis
10.10.3.1. Ethosuximide
10.10.3.2. Felbamate
10.10.3.3. Gabapentin
10.10.3.4. Lamotrigine
10.10.3.5. Pregabaline
10.10.3.6. Topiramate
10.10.3.7. Zonisamide
10.10.3.8. Carbamazepine
10.10.3.9. Valproic Acid
10.10.3.10. Lacosamide
10.10.3.11. Levetiracetam
10.10.3.12. Phenobarbital
10.10.3.13. Phenytoin
10.10.3.14. Rufinamide
10.10.3.15. Tiagabine
10.10.3.16. Vigabatrin
10.10.3.17. Primidone
10.11. Anti-HIV
10.11.1. Anti-HIV Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
10.11.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
10.11.3. Market Opportunity Analysis
10.11.3.1. Atazanavir
10.11.3.2. Indinavir
10.11.3.3. Lopinavir
10.11.3.4. Nelfinavir
10.11.3.5. Ritonavir
10.11.3.6. Saquinavir
10.11.3.7. Darunavir
10.11.3.8. Fosamprenavir
10.11.3.9. Tipranavir
10.11.3.10. Efavirenz
10.11.3.11. Etravirine
10.11.3.12. Nevirapine
10.11.3.13. Rilpivirine
10.12. Antihypertensive
10.12.1. Antihypertensive Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
10.12.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
10.12.3. Market Opportunity Analysis
10.12.3.1. Propronolol
10.13. Antipsychotics
10.13.1. Antipsychotics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
10.13.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
10.13.3. Market Opportunity Analysis
10.13.3.1. Aripiprazole
10.13.3.2. Clozapine
10.13.3.3. Haloperidol
10.13.3.4. Olanzapine
10.13.3.5. Ziprasidone
10.13.3.6. Chlorpromazine
10.13.3.7. Lithium
10.13.3.8. Lurasidone
10.13.3.9. Paliperidone
10.13.3.10. Perphenazine
10.13.3.11. Quetiapine
10.13.3.12. Risperidone
10.13.3.13. Thiothixene
10.14. Hormones
10.14.1. Hormones Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
10.14.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
10.14.3. Market Opportunity Analysis
10.14.3.1. T3
10.14.3.2. T4
10.14.3.3. Corticosteroids
10.14.3.4. TSH
10.15. Immuno-Suppressants
10.15.1. Immuno-Suppressants Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
10.15.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
10.15.3. Market Opportunity Analysis
10.15.3.1. Cyclosporin A
10.15.3.2. Everolimus
10.15.3.3. Mycophenolic acid
10.15.3.4. Sirolimus
10.15.3.5. Tacrolimus
10.16. Antifungals
10.16.1. Antifungals Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
10.16.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
10.16.3. Market Opportunity Analysis
10.16.3.1. Fluconazole
10.16.3.2. Itraconazole
10.16.3.3. Voriconazole
10.16.3.4. Posoconazole
10.17. Immuno- Assay
10.17.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions))
10.17.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
10.17.3. Market Opportunity Analysis
10.18. Mass Spectrometry
10.18.1. LC-MS/MS
10.18.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions))
10.18.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
10.18.1.3. Market Opportunity Analysis
10.18.2. GC-MS/MS
10.18.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions))
10.18.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
10.18.2.3. Market Opportunity Analysis
10.19. Others (Electrophoresis, Proteomics, etc.)
10.19.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions))
10.19.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
10.19.3. Market Opportunity Analysis
10.20. Europe, Middle East & Africa Therapeutic Drug Monitoring (TDM) Market By End User
10.20.1. Hospital Laboratories
10.20.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions))
10.20.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
10.20.1.3. Market Opportunity Analysis
10.20.2. Private Laboratories
10.20.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions))
10.20.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
10.20.2.3. Market Opportunity Analysis
10.21. Europe, Middle East & Africa Therapeutic Drug Monitoring (TDM) Market By Country
10.21.1. U.K.
10.21.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions))
10.21.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
10.21.1.3. Market Opportunity Analysis
10.21.2. Germany
10.21.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions))
10.21.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
10.21.2.3. Market Opportunity Analysis
10.21.3. France
10.21.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions))
10.21.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
10.21.3.3. Market Opportunity Analysis
10.21.4. Italy
10.21.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions))
10.21.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
10.21.4.3. Market Opportunity Analysis
10.21.5. Belgium
10.21.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions))
10.21.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
10.21.5.3. Market Opportunity Analysis
10.21.6. Spain
10.21.6.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions))
10.21.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
10.21.6.3. Market Opportunity Analysis
10.21.7. Rest of Europe, Middle East and Africa
10.21.7.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions))
10.21.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
10.21.7.3. Market Opportunity Analysis
10.22. Europe, Middle East & Africa Therapeutic Drug Monitoring (TDM) Market Dynamics – Trends
11. Latin America Therapeutic Drug Monitoring (TDM) Market Analysis, 2017 – 2021 and Forecast, 2018 – 2028
11.1. Antibiotics
11.1.1. Antibiotics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
11.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
11.1.3. Market Opportunity Analysis
11.1.3.1. Chloramphenicol
11.1.3.2. Linezolid
11.1.3.3. Piperacillin
11.1.3.4. Rifampicin
11.1.3.5. Tazobactam
11.1.3.6. Vancomycin
11.1.3.7. Gentamicin
11.1.3.8. Amikacin
11.1.3.9. Tobramycin
11.1.3.10. Teicoplanin
11.1.3.11. Ceftazidime
11.1.3.12. Meropenem
11.1.3.13. Nafcillin
11.1.3.14. Ticarcillin
11.2. Addiction Therapeutics
11.2.1. Addiction Therapeutics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
11.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
11.2.3. Market Opportunity Analysis
11.2.3.1. Buprenorphine
11.2.3.2. Methadone
11.2.3.3. Naltrexone
11.2.3.4. Propoxyphene
11.2.3.5. Tapentadol
11.3. Alzheimer Disease
11.3.1. Alzheimer Disease Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
11.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
11.3.3. Market Opportunity Analysis
11.3.3.1. Donezepil
11.3.3.2. Galantamine
11.3.3.3. Memantine
11.4. Analeptics
11.4.1. Analeptics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
11.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
11.4.3. Market Opportunity Analysis
11.4.3.1. Caffeine
11.4.3.2. Theophylline
11.5. Analgesics
11.5.1. Analgesics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
11.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
11.5.3. Market Opportunity Analysis
11.5.3.1. Acetaminophen
11.5.3.2. Ibuprofen
11.5.3.3. Naproxen
11.5.3.4. Salicylate
11.5.3.5. Tramadol
11.6. Antiarrhythmic
11.6.1. Antiarrythmic Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
11.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
11.6.3. Market Opportunity Analysis
11.6.3.1. Amiodarone
11.6.3.2. Digoxin
11.6.3.3. Flecainide
11.6.3.4. Mexiletine
11.6.3.5. Verapamil
11.6.3.6. N-acetylprocainamide, NAPA
11.6.3.7. Digitoxin
11.6.3.8. Lidocaine
11.6.3.9. Procainimide
11.6.3.10. Quinidine
11.7. Anticancer
11.7.1. Anticancer Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
11.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
11.7.3. Market Opportunity Analysis
11.7.3.1. 5-Fluorouracil
11.7.3.2. Docetaxel
11.7.3.3. Methotrexate
11.7.3.4. Mylmatinib
11.7.3.5. Paclitaxel
11.7.3.6. Imatinib
11.7.3.7. Busulfan
11.8. Anticoagulants
11.8.1. Anticoagulants Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
11.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
11.8.3. Market Opportunity Analysis
11.8.3.1. Dabigatran
11.8.3.2. Warfarin
11.9. Antidepressants
11.9.1. Antidepressants Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
11.9.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
11.9.3. Market Opportunity Analysis
11.9.3.1. Citalopram
11.9.3.2. Fluoxetine
11.9.3.3. Fluvoxamine
11.9.3.4. Sertraline
11.9.3.5. Venlafaxine
11.9.3.6. Desmethylfluoxetine
11.9.3.7. Trazodone
11.9.3.8. Protriptyline
11.9.3.9. Nortriptyline
11.9.3.10. Imipramine
11.9.3.11. Desipramine
11.9.3.12. Doxepin
11.9.3.13. Clomipramine
11.9.3.14. Bupropion
11.9.3.15. Amitriptyline
11.9.3.16. Nortriptyline
11.10. Antiepileptics
11.10.1. Antiepileptics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
11.10.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
11.10.3. Market Opportunity Analysis
11.10.3.1. Ethosuximide
11.10.3.2. Felbamate
11.10.3.3. Gabapentin
11.10.3.4. Lamotrigine
11.10.3.5. Pregabaline
11.10.3.6. Topiramate
11.10.3.7. Zonisamide
11.10.3.8. Carbamazepine
11.10.3.9. Valproic Acid
11.10.3.10. Lacosamide
11.10.3.11. Levetiracetam
11.10.3.12. Phenobarbital
11.10.3.13. Phenytoin
11.10.3.14. Rufinamide
11.10.3.15. Tiagabine
11.10.3.16. Vigabatrin
11.10.3.17. Primidone
11.11. Anti-HIV
11.11.1. Anti-HIV Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
11.11.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
11.11.3. Market Opportunity Analysis
11.11.3.1. Atazanavir
11.11.3.2. Indinavir
11.11.3.3. Lopinavir
11.11.3.4. Nelfinavir
11.11.3.5. Ritonavir
11.11.3.6. Saquinavir
11.11.3.7. Darunavir
11.11.3.8. Fosamprenavir
11.11.3.9. Tipranavir
11.11.3.10. Efavirenz
11.11.3.11. Etravirine
11.11.3.12. Nevirapine
11.11.3.13. Rilpivirine
11.12. Antihypertensive
11.12.1. Antihypertensive Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
11.12.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
11.12.3. Market Opportunity Analysis
11.12.3.1. Propronolol
11.13. Antipsychotics
11.13.1. Antipsychotics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
11.13.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
11.13.3. Market Opportunity Analysis
11.13.3.1. Aripiprazole
11.13.3.2. Clozapine
11.13.3.3. Haloperidol
11.13.3.4. Olanzapine
11.13.3.5. Ziprasidone
11.13.3.6. Chlorpromazine
11.13.3.7. Lithium
11.13.3.8. Lurasidone
11.13.3.9. Paliperidone
11.13.3.10. Perphenazine
11.13.3.11. Quetiapine
11.13.3.12. Risperidone
11.13.3.13. Thiothixene
11.14. Hormones
11.14.1. Hormones Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
11.14.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
11.14.3. Market Opportunity Analysis
11.14.3.1. T3
11.14.3.2. T4
11.14.3.3. Corticosteroids
11.14.3.4. TSH
11.15. Immuno-Suppressants
11.15.1. Immuno-Suppressants Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
11.15.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
11.15.3. Market Opportunity Analysis
11.15.3.1. Cyclosporin A
11.15.3.2. Everolimus
11.15.3.3. Mycophenolic acid
11.15.3.4. Sirolimus
11.15.3.5. Tacrolimus
11.16. Antifungals
11.16.1. Antifungals Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
11.16.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
11.16.3. Market Opportunity Analysis
11.16.3.1. Fluconazole
11.16.3.2. Itraconazole
11.16.3.3. Voriconazole
11.16.3.4. Posoconazole
11.17. Immuno- Assay
11.17.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions))
11.17.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
11.17.3. Market Opportunity Analysis
11.18. Mass Spectrometry
11.18.1. LC-MS/MS
11.18.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions))
11.18.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
11.18.1.3. Market Opportunity Analysis
11.18.2. GC-MS/MS
11.18.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions))
11.18.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
11.18.2.3. Market Opportunity Analysis
11.19. Others (Electrophoresis, Proteomics, etc.)
11.19.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions))
11.19.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
11.19.3. Market Opportunity Analysis
11.20. Latin America Therapeutic Drug Monitoring (TDM) Market By End User
11.20.1. Hospital Laboratories
11.20.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions))
11.20.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
11.20.1.3. Market Opportunity Analysis
11.20.2. Private Laboratories
11.20.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions))
11.20.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
11.20.2.3. Market Opportunity Analysis
11.21. Latin America Therapeutic Drug Monitoring (TDM) Market By Country
11.21.1. Brazil
11.21.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions))
11.21.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
11.21.1.3. Market Opportunity Analysis
11.21.2. Rest of LATAM
11.21.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions))
11.21.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
11.21.2.3. Market Opportunity Analysis
11.22. Latin America Therapeutic Drug Monitoring (TDM) Market Dynamics – Trends
12. Asia-Pacific Therapeutic Drug Monitoring (TDM) Market Analysis, 2017 – 2021 and Forecast, 2018 – 2028
12.1. Antibiotics
12.1.1. Antibiotics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
12.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
12.1.3. Market Opportunity Analysis
12.1.3.1. Chloramphenicol
12.1.3.2. Linezolid
12.1.3.3. Piperacillin
12.1.3.4. Rifampicin
12.1.3.5. Tazobactam
12.1.3.6. Vancomycin
12.1.3.7. Gentamicin
12.1.3.8. Amikacin
12.1.3.9. Tobramycin
12.1.3.10. Teicoplanin
12.1.3.11. Ceftazidime
12.1.3.12. Meropenem
12.1.3.13. Nafcillin
12.1.3.14. Ticarcillin
12.2. Addiction Therapeutics
12.2.1. Addiction Therapeutics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
12.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
12.2.3. Market Opportunity Analysis
12.2.3.1. Buprenorphine
12.2.3.2. Methadone
12.2.3.3. Naltrexone
12.2.3.4. Propoxyphene
12.2.3.5. Tapentadol
12.3. Alzheimer Disease
12.3.1. Alzheimer Disease Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
12.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
12.3.3. Market Opportunity Analysis
12.3.3.1. Donezepil
12.3.3.2. Galantamine
12.3.3.3. Memantine
12.4. Analeptics
12.4.1. Analeptics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
12.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
12.4.3. Market Opportunity Analysis
12.4.3.1. Caffeine
12.4.3.2. Theophylline
12.5. Analgesics
12.5.1. Analgesics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
12.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
12.5.3. Market Opportunity Analysis
12.5.3.1. Acetaminophen
12.5.3.2. Ibuprofen
12.5.3.3. Naproxen
12.5.3.4. Salicylate
12.5.3.5. Tramadol
12.6. Antiarrhythmic
12.6.1. Antiarrythmic Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
12.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
12.6.3. Market Opportunity Analysis
12.6.3.1. Amiodarone
12.6.3.2. Digoxin
12.6.3.3. Flecainide
12.6.3.4. Mexiletine
12.6.3.5. Verapamil
12.6.3.6. N-acetylprocainamide, NAPA
12.6.3.7. Digitoxin
12.6.3.8. Lidocaine
12.6.3.9. Procainimide
12.6.3.10. Quinidine
12.7. Anticancer
12.7.1. Anticancer Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
12.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
12.7.3. Market Opportunity Analysis
12.7.3.1. 5-Fluorouracil
12.7.3.2. Docetaxel
12.7.3.3. Methotrexate
12.7.3.4. Mylmatinib
12.7.3.5. Paclitaxel
12.7.3.6. Imatinib
12.7.3.7. Busulfan
12.8. Anticoagulants
12.8.1. Anticoagulants Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
12.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
12.8.3. Market Opportunity Analysis
12.8.3.1. Dabigatran
12.8.3.2. Warfarin
12.9. Antidepressants
12.9.1. Antidepressants Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
12.9.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
12.9.3. Market Opportunity Analysis
12.9.3.1. Citalopram
12.9.3.2. Fluoxetine
12.9.3.3. Fluvoxamine
12.9.3.4. Sertraline
12.9.3.5. Venlafaxine
12.9.3.6. Desmethylfluoxetine
12.9.3.7. Trazodone
12.9.3.8. Protriptyline
12.9.3.9. Nortriptyline
12.9.3.10. Imipramine
12.9.3.11. Desipramine
12.9.3.12. Doxepin
12.9.3.13. Clomipramine
12.9.3.14. Bupropion
12.9.3.15. Amitriptyline
12.9.3.16. Nortriptyline
12.10. Antiepileptics
12.10.1. Antiepileptics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
12.10.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
12.10.3. Market Opportunity Analysis
12.10.3.1. Ethosuximide
12.10.3.2. Felbamate
12.10.3.3. Gabapentin
12.10.3.4. Lamotrigine
12.10.3.5. Pregabaline
12.10.3.6. Topiramate
12.10.3.7. Zonisamide
12.10.3.8. Carbamazepine
12.10.3.9. Valproic Acid
12.10.3.10. Lacosamide
12.10.3.11. Levetiracetam
12.10.3.12. Phenobarbital
12.10.3.13. Phenytoin
12.10.3.14. Rufinamide
12.10.3.15. Tiagabine
12.10.3.16. Vigabatrin
12.10.3.17. Primidone
12.11. Anti-HIV
12.11.1. Anti-HIV Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
12.11.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
12.11.3. Market Opportunity Analysis
12.11.3.1. Atazanavir
12.11.3.2. Indinavir
12.11.3.3. Lopinavir
12.11.3.4. Nelfinavir
12.11.3.5. Ritonavir
12.11.3.6. Saquinavir
12.11.3.7. Darunavir
12.11.3.8. Fosamprenavir
12.11.3.9. Tipranavir
12.11.3.10. Efavirenz
12.11.3.11. Etravirine
12.11.3.12. Nevirapine
12.11.3.13. Rilpivirine
12.12. Antihypertensive
12.12.1. Antihypertensive Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
12.12.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
12.12.3. Market Opportunity Analysis
12.12.3.1. Propronolol
12.13. Antipsychotics
12.13.1. Antipsychotics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
12.13.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
12.13.3. Market Opportunity Analysis
12.13.3.1. Aripiprazole
12.13.3.2. Clozapine
12.13.3.3. Haloperidol
12.13.3.4. Olanzapine
12.13.3.5. Ziprasidone
12.13.3.6. Chlorpromazine
12.13.3.7. Lithium
12.13.3.8. Lurasidone
12.13.3.9. Paliperidone
12.13.3.10. Perphenazine
12.13.3.11. Quetiapine
12.13.3.12. Risperidone
12.13.3.13. Thiothixene
12.14. Hormones
12.14.1. Hormones Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
12.14.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
12.14.3. Market Opportunity Analysis
12.14.3.1. T3
12.14.3.2. T4
12.14.3.3. Corticosteroids
12.14.3.4. TSH
12.15. Immuno-Suppressants
12.15.1. Immuno-Suppressants Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
12.15.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
12.15.3. Market Opportunity Analysis
12.15.3.1. Cyclosporin A
12.15.3.2. Everolimus
12.15.3.3. Mycophenolic acid
12.15.3.4. Sirolimus
12.15.3.5. Tacrolimus
12.16. Antifungals
12.16.1. Antifungals Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients)
12.16.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
12.16.3. Market Opportunity Analysis
12.16.3.1. Fluconazole
12.16.3.2. Itraconazole
12.16.3.3. Voriconazole
12.16.3.4. Posoconazole
12.17. Immuno- Assay
12.17.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions))
12.17.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
12.17.3. Market Opportunity Analysis
12.18. Mass Spectrometry
12.18.1. LC-MS/MS
12.18.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions))
12.18.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
12.18.1.3. Market Opportunity Analysis
12.18.2. GC-MS/MS
12.18.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions))
12.18.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
12.18.2.3. Market Opportunity Analysis
12.19. Others (Electrophoresis, Proteomics, etc.)
12.19.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions))
12.19.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
12.19.3. Market Opportunity Analysis
12.20. Asia-Pacific Therapeutic Drug Monitoring (TDM) Market By End User
12.20.1. Hospital Laboratories
12.20.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions))
12.20.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
12.20.1.3. Market Opportunity Analysis
12.20.2. Private Laboratories
12.20.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions))
12.20.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
12.20.2.3. Market Opportunity Analysis
12.21. Asia-Pacific Therapeutic Drug Monitoring (TDM) Market By Country
12.21.1. Japan
12.21.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions))
12.21.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
12.21.1.3. Market Opportunity Analysis
12.21.2. China
12.21.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions))
12.21.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
12.21.2.3. Market Opportunity Analysis
12.21.3. Australia
12.21.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions))
12.21.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
12.21.3.3. Market Opportunity Analysis
12.21.4. S.Korea
12.21.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions))
12.21.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
12.21.4.3. Market Opportunity Analysis
12.22. Asia-Pacific Therapeutic Drug Monitoring (TDM) Market Dynamics – Trends
13. Competition Landscape 
13.1. Strategic Dashboard of Top Market Players
13.2. Company Profiles (Introduction, Financial Analysis, Analyte & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
13.2.1. Beckman Coulter Inc. (U.S.)
13.2.2. Hoffmann-La Roche (U.S.)
13.2.3. Bio-Rad Laboratories Inc. (U.S.)
13.2.4. Thermo Fisher Scientific (U.S.)
13.2.5. Siemens Healthineers (Siemens AG (Germany)
13.2.6. Abbott (Alere Inc.) (U.S.)
13.2.7. Diagnostics GmbH (Germany)
13.2.8. Grifols (Spain)
13.2.9. BÜHLMANN Laboratories AG (Germany)
13.2.10. bioMérieux (U.S.)
13.2.11. Merck Millipore (E. Merck KG) (Germany)
13.2.12. DiaSorin (Italy)
13.2.13. Myriad Genetics (U.S.)
13.2.14. Miraca Life Sciences (Miraca Holdings Inc.) (Japan)
13.2.15. Roche Diagnostics (Switzerland)
13.2.16. Chromsystems (Germany)
13.2.17. Phamatech, Inc (U.S.)
13.2.18. Randox Laboratories Ltd. (U.K.)
13.2.19. SEKISUI MEDICAL CO., LTD. (Japan)
14. Research Methodology
15. Key Assumptions and Acronyms

Report

Company Profile

  • ARK Diagnostics, Inc.
  • Beckman Coulter
  • Ortho Clinical Diagnostics
  • Sekisui Diagnostics
  • SJK Global, LLC
  • Chromsystems
  • Meridian Healthcare S.R.L.
  • Randox Laboratories Ltd
  • Sekisui Medical Co. Ltd.
  • Thermo Fisher Scientific
  • North American Science Associates, Inc.
  • Ortho Clinical Diagnostics, Randox Laboratories Ltd
  • Alfa Scientific Designs, Inc.
  • Carolina Liquid Chemistries
  • Concateno (Alere)
  • DiaSystem Scandinevia AB
  • First Check Diagnostics
  • Alfa Scientific Designs, Inc.
  • Orasure Technologies, Inc

Description

Therapeutic Drug Monitoring Market size was valued at USD 2.2 billion in 2021. It is expected to reach a value of USD 3.5 billion by 2028, witnessing at a CAGR rate of 4.9% from 2022-2028. Therapeutic Drug Monitoring is a measurement of drug concentrations or drug metabolites in plasma. It is usually carried out for narrow therapeutic index drugs. Therapeutic drug monitoring is the clinical assessment of drug’s pharmacokinetic properties. TDM helps in reduce drug toxicity, enhance drug efficacy and diagnostic purpose. Various drug molecules usually monitored at clinical practice. For example: drugs like digoxin, cyclosporin, phenytoin, carbamazepine and valproic acid, among others. Tricyclic antidepressants (TCAs) such as Amitriptyline, Nortriptyline, Imipramine, and Clomipramine are frequently preferred for TDM due to their slow onset of action the difficulty of assessing dose-effect, and the marked interindividual variability of steady-state plasma concentration. In general, LC-MS/MS is highly preferred for TDM of tricyclic antidepressants due to structural similarity of the drugs. Immunosuppressant drugs are mostly used in organ transplantation cases. Patients using ISD’s commonly undergo TDM owing to their narrow therapeutic index, variability in blood concentrations between individuals and severe adverse effects. In terms of technology, LC-MS/MS accounts for more than USD 730 Million in 2018 followed by immunoassay, Others and GC/GC-MS. In terms of value, LC-MS/MS dominate the global TDM market followed by the immunoassays segment owing to its sensitivity, specificity towards the identification analytes and simultaneous analysis of the multiple drugs and analytes in the blood. However, in terms of volume Immunoassays dominate the market and they are cost effective when compared with other reagents. The report gives historical, current, and future market sizes (US$ Bn) based on Technology, Drug class, and Geography. This report studies market dynamics elaborately to identify the current trends & drivers, future opportunities, and possible challenges to the key stakeholders operating in the market. In addition, the report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition.

Key Development:

In March 2022, Beckman Coulter, a global clinical diagnostics leader, announced that the company will introduce new antipsychotic drug tests to laboratories and clinicians to address an unmet clinical need for 69 million people with serious mental conditions worldwide. In a new agreement with Saladax Biomedical, Inc., Beckman Coulter will distribute the tests designed to measure blood levels of antipsychotic drugs prescribed to treat patients with serious mental illness (SMI), such as Schizophrenia and Bipolar Disorder. These new assays are developed using an innovative nanoparticle technology and empower health care professionals with data to monitor psychiatric drugs prescribed in treatment of psychosis: Clozapine, Risperidone/Paliperidone, Olanzapine, Quetiapine, Aripiprazole.

In August 2019, Ortho Clinical Diagnostics, a global leader in in-vitro diagnostics, in collaboration with Thermo Fisher Scientific, has expanded Drugs of Abuse and Therapeutic Drug Assay menus on MicroTip-capable VITROS® Systems to enable testing for fentanyl, a commonly abused opioid, and tricyclic antidepressant (TCA), which has a narrow safe therapeutic range.

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX